NYSE$BHC

Bausch Health Companies Inc · Q3 2020 earnings

Q3 2020 earnings · · Investor relations

Briefing

Third quarter results demonstrated recovery from the COVID-19 pandemic.

Bausch Health's third-quarter 2020 results demonstrated recovery from the COVID-19 pandemic with total company reported revenue growing 28% sequentially from the second quarter. The company reaffirmed its 2020 full-year revenue and adjusted EBITDA guidance ranges.

  • Revenues of $2.138 Billion
  • GAAP Net Income of $71 Million
  • Adjusted EBITDA (non-GAAP) of $948 Million
  • GAAP Cash Generated from Operations of $256 Million

Headline financials

Total Revenue

$2.14B

Previous: $2.21B-3.2%
EPS (adj)

$1.32

Previous: $1.19+10.9%
Adjusted EBITDA

$948M

Previous: $942M+0.6%
Cash from Operations

$256M

Previous: $515M-50.3%
Capital Expenditures

-$222M

Previous: -$192M-15.6%
Free Cash Flow

-$152M

Previous: -$240M+36.7%
Net Income

$70M

Previous: -$48M+245.8%
Operating Income

$460M

Previous: $329M+39.8%
Gross Profit

$1.55B

Previous: $0.00
Cash & Equivalents

$977M

Previous: $825M+18.4%
Total Assets

$31.6B

Previous: $31.7B-0.3%
Stock-Based Comp

$27M

Previous: $26M+3.8%

Revenue & EPS history

Bausch Health · Revenue · Quarterly

$2.14B

Q3 2020-3.2%vs Q3 2019
Beat estimate in 12 of 16 quarters(75%)
ActualEstimate

Revenue by segment

Bausch Health · $2.14B total across 4 segments · Q3 2020

  • Bausch + Lomb/International
    $1.17B-0.5%
  • Salix
    $496M-10.0%
  • Diversified Products
    $329M-2.1%
  • Ortho Dermatologics
    $144M-2.0%

Forward guidance

Bausch Health reaffirmed its revenue and Adjusted EBITDA guidance ranges for the full year of 2020, reflecting management’s current expectations.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q3 2020

Historical avgQ3 2020

+0.2%

Avg return

Earnings day

-0.6%

Avg return

5 days after

-1.9%

Avg return

30 days after

51%

35 / 68 earnings

Positive

+30.6%

Q1 2017

Best reaction

-21.5%

Q1 2022

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026+10.9%+0.9%-4.1%
Q4 2025-4.5%-2.7%-19.1%
Q3 2025+12.4%+14.2%+7.6%
Q1 2025+0.0%-10.6%-14.5%
Q4 2024+10.3%+15.8%+10.0%
Q3 2024+12.7%+13.5%+2.6%
Q2 2024-6.6%-10.6%-1.7%
Q1 2024-10.6%-15.3%-25.0%
Q4 2023+5.9%+5.9%+10.3%
Q3 2023+6.9%+2.4%+4.0%
Q2 2023-2.9%-4.6%-9.3%
Q1 2023-21.2%-20.8%+11.2%
Q4 2022+10.8%+7.8%-16.3%
Q3 2022+7.5%+8.4%+21.4%
Q2 2022-3.3%+2.9%+14.7%
Q1 2022-21.5%-16.0%-35.0%
Q4 2021-1.9%+1.9%-3.3%
Q3 2021-4.5%-1.9%-17.8%
Q2 2021-15.5%-10.1%-0.7%
Q1 2021-10.8%-10.6%+0.9%
Q4 2020-0.9%+0.6%-1.8%
Q3 2020-3.1%-4.0%+11.0%
Q2 2020-7.2%-9.2%-16.3%
Q1 2020-1.8%+0.2%+12.4%
Q4 2019-5.8%-7.3%-51.3%
Q3 2019+0.8%+1.1%+10.6%
Q2 2019-4.0%-3.0%-6.9%
Q1 2019+8.7%+8.0%-9.0%
Q4 2018-6.7%-7.3%-2.0%
Q3 2018+6.1%+6.4%-5.2%
Q2 2018+5.4%-2.9%-7.3%
Q1 2018+11.5%+14.8%+37.4%
Q4 2017-17.5%-16.8%-13.9%
Q3 2017+23.6%+27.7%+46.4%
Q2 2017-8.5%-9.6%-12.9%
Q1 2017+30.6%+40.0%+36.6%
Q4 2016-18.7%-21.8%-33.7%
Q3 2016-15.9%-5.9%-19.3%
Q2 2016+21.7%+11.0%+33.5%
Q1 2016-17.1%-16.3%-18.6%
Q4 2015-7.4%
Q3 2015-17.4%
Q2 2015+5.4%
Q1 2015+5.6%
Q4 2014+14.7%
Q3 2014+8.5%
Q2 2014-6.1%
Q1 2014-1.6%
Q4 2013-1.0%
Q3 2013+2.0%
Q2 2013+6.2%
Q1 2013+1.8%
Q4 2012+1.3%
Q3 2012-2.6%
Q2 2012+2.2%
Q1 2012+2.1%
Q4 2008+6.3%
Q4 2010+6.3%
Q4 2011+6.3%
Q3 2011-2.9%
Q2 2011+3.9%
Q1 2010+0.0%
Q1 2011+6.3%
Q3 2010-5.4%
Q3 2009-5.4%
Q2 2009+2.0%
Q2 2010+2.0%
Q4 2009+2.0%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro